MET and neoplasm: This “ecDNA-templated” RTK rearrangement effectively reprograms the tumor signaling axis at the cellular population level from EGFR to PDGFRA dependency, recapitulating features of the RTK-switch phenomena seen in other malignancies under targeted pressure (e.g., MET amplification after EGFR inhibition)46–48.